Search

UX111 (Ultragenyx Pharmaceutical Inc.) for Mucopolysaccharidosis Type IIIA

An investigational single-infusion gene therapy proposed for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).

Complete this form to request the full report